Characteristics | n (%) |
---|---|
Follow-up duration, months, median (range) | 35.3 (4.1–52.9) |
Age, years, median (range) | 70 (47–86) |
T stage | Â |
 1c | 49 (19.4%) |
 2a | 79 (31.2%) |
 2b | 35 (13.8%) |
 2c | 53 (20.9%) |
 3a | 27 (10.7%) |
 3b | 10 (4.0%) |
Pretreatment PSA, ng/ml, median (range) | 8.6 (3.33–187) |
 < 10 | 147 (58.1%) |
 10 ≤ 20 | 73 (28.9%) |
 20 ≤ | 33 (13.0%) |
Gleason score | Â |
 6 | 14 (5.5%) |
 7 | 117 (46.2%) |
 8 | 79 (31.2%) |
 9 | 43 (17.0%) |
 10 | 0 (0.0%) |
D’Amico classification |  |
 low | 8 (3.2%) |
 intermediate | 88 (34.8%) |
 high | 157 (62.1%) |
ADT | Â |
 none | 9 (3.6%) |
 neoadjuvant | 87 (34.4%) |
 neoadjuvant and adjuvant | 157 (62.1%) |
Complications, histories | Â |
 Diabetes mellitus | 25 (9.9%) |
 Internal use of anticoagulants | 41 (16.2%) |
 Benign prostate hyperplasia | 18 (7.1%) |
 TURP | 4 (1.6%) |